NCT02101918: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 99 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02101918 |
|---|---|
| Title | Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 18, 2014 |
| Completion date | Jan. 31, 2018 |
| Required reporting date | Jan. 31, 2019, midnight |
| Actual reporting date | May 10, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 99 |